FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

0			٠	•••	
ashington	DC	20549	a		

l	OMB APPROVAL										
	OMB Number:	3235-0287									
l	Estimated average burden										

hours per response:

0.5

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5 obligations may continue. See
J	obligations may continue. See
	Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SPIVEY RON J				2. Issuer Name and Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC ACUR.OB								(Check	5. Relationship of Reporting (Check all applicable) Director Officer (give title			Person(s) to Issuer 10% Owner Other (specify			
(Last) (First) (Middle) C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120				3. Date of Earliest Transaction (Month/Day/Year) 12/09/2005								_ X	X Officer (give title Officer Scientific Officer						
(Street)	NE II	L	60067		4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indiv	S. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person								
(City)	(5	State)	(Zip)																
			Table I - Non-	Deriv	ative	Securitie	s Ac	cqui	red, D	ispo	osed c	of, or Be	nefi	cially O	wned				
Date				Saction 2A. Deemed Execution Day (Month/Day/Year) (Month/Day/Year)		Date	Code (Instr.		ion I	4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Following R	Owned eported	6. Own Form: I (D) or I (I) (Inst	Direct Ir ndirect B r. 4) O	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						[Code V Amou		Amount	t (A) or Pr		Price	(Instr. 3 and 4)				11501. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			le and	7. Title and Amou Securities Underly Derivative Securit 3 and 4)		erlying	8. Price of Derivative Security (Instr. 5)	e derivati	ve ies ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exer	e rcisable	Exp Date	oiration e	Title		ount or ober of res		Transaction(s) (Instr. 4)			
Employee Stock Options	\$0.13	12/09/2005		A		4,000,000 ⁽¹⁾			(2)	12/0	09/2015	Common Stock	4,00	00,000(1)	\$0	7,000	,000	D	

Explanation of Responses:

- $1.\ Option\ to\ purchase\ 4,000,000\ shares\ of\ Issuer's\ common\ stock,\ \$.01\ par\ value\ per\ share.$
- 2. Option vests as follows: (a) 3,555,334 options vest on 01/01/06 and (b) 444,666 options vest on 04/01/06. Options are intended to comply with Section 409A of the Internal Revenue Code, and as a result exercisability is not coincident with vesting. Option Agreement is being prepared.

12/12/2005 /s/ Ron J. Spivey

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.